164 related articles for article (PubMed ID: 19515771)
1. Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine.
van der Sanden S; Pallansch MA; van de Kassteele J; El-Sayed N; Sutter RW; Koopmans M; van der Avoort H
J Virol; 2009 Sep; 83(17):8693-704. PubMed ID: 19515771
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.
Estívariz CF; Anand A; Gary HE; Rahman M; Islam J; Bari TI; Wassilak SG; Chu SY; Weldon WC; Pallansch MA; Heffelfinger JD; Luby SP; Zaman K
Lancet Infect Dis; 2015 Aug; 15(8):898-904. PubMed ID: 26093980
[TBL] [Abstract][Full Text] [Related]
3. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials.
John TJ; Jain H; Ravishankar K; Amaresh A; Verma H; Deshpande J; Pallansch MA; Singh AP; Sreevatsava M; Burton A; Malankar P; Chatterjee A; Sutter RW
Vaccine; 2011 Aug; 29(34):5793-801. PubMed ID: 21641951
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
[TBL] [Abstract][Full Text] [Related]
5. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.
Mir F; Quadri F; Mach O; Ahmed I; Bhatti Z; Khan A; Rehman NU; Durry E; Salama M; Oberste SM; Weldon WC; Sutter RW; Zaidi AK
Lancet Infect Dis; 2015 Aug; 15(8):889-97. PubMed ID: 26093979
[TBL] [Abstract][Full Text] [Related]
6. Monovalent type 1 oral poliovirus vaccine in newborns.
el-Sayed N; el-Gamal Y; Abbassy AA; Seoud I; Salama M; Kandeel A; Hossny E; Shawky A; Hussein HA; Pallansch MA; van der Avoort HG; Burton AH; Sreevatsava M; Malankar P; Wahdan MH; Sutter RW
N Engl J Med; 2008 Oct; 359(16):1655-65. PubMed ID: 18923170
[TBL] [Abstract][Full Text] [Related]
7. Long-term excretion of vaccine-derived poliovirus by a healthy child.
Martín J; Odoom K; Tuite G; Dunn G; Hopewell N; Cooper G; Fitzharris C; Butler K; Hall WW; Minor PD
J Virol; 2004 Dec; 78(24):13839-47. PubMed ID: 15564492
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa.
Waggie Z; Geldenhuys H; Sutter RW; Jacks M; Mulenga H; Mahomed H; De Kock M; Hanekom W; Pallansch MA; Kahn AL; Burton AH; Sreevatsava M; Hussey G
J Infect Dis; 2012 Jan; 205(2):228-36. PubMed ID: 22158680
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.
Estívariz CF; Jafari H; Sutter RW; John TJ; Jain V; Agarwal A; Verma H; Pallansch MA; Singh AP; Guirguis S; Awale J; Burton A; Bahl S; Chatterjee A; Aylward RB
Lancet Infect Dis; 2012 Feb; 12(2):128-35. PubMed ID: 22071249
[TBL] [Abstract][Full Text] [Related]
10. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
[TBL] [Abstract][Full Text] [Related]
11. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
[TBL] [Abstract][Full Text] [Related]
12. Determinants of monovalent oral polio vaccine mutagenesis in vaccinated elderly people.
Boot HJ; Sonsma J; van Nunen F; Abbink F; Kimman TG; Buisman AM
Vaccine; 2007 Jun; 25(24):4706-14. PubMed ID: 17482726
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1.
Blomqvist S; Bruu AL; Stenvik M; Hovi T
J Gen Virol; 2003 Mar; 84(Pt 3):573-580. PubMed ID: 12604808
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of an environmentally monitored prolonged type 2 vaccine derived poliovirus shedding episode that stopped without intervention.
Hovi T; Paananen A; Blomqvist S; Savolainen-Kopra C; Al-Hello H; Smura T; Shimizu H; Nadova K; Sobotova Z; Gavrilin E; Roivainen M
PLoS One; 2013; 8(7):e66849. PubMed ID: 23935826
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia.
Blomqvist S; Savolainen C; Laine P; Hirttiö P; Lamminsalo E; Penttilä E; Jöks S; Roivainen M; Hovi T
J Virol; 2004 May; 78(9):4876-83. PubMed ID: 15078968
[TBL] [Abstract][Full Text] [Related]
16. Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
Snider CJ; Zaman K; Wilkinson AL; Binte Aziz A; Yunus M; Haque W; Jones KAV; Wei L; Estivariz CF; Konopka-Anstadt JL; Mainou BA; Patel JC; Lickness JS; Pallansch MA; Wassilak SGF; Steven Oberste M; Anand A
Vaccine; 2023 Sep; 41(41):6083-6092. PubMed ID: 37652822
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
[TBL] [Abstract][Full Text] [Related]
18. Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Córdoba Province, Argentina.
Mueller JE; Bessaud M; Huang QS; Martinez LC; Barril PA; Morel V; Balanant J; Bocacao J; Hewitt J; Gessner BD; Delpeyroux F; Nates SV
Appl Environ Microbiol; 2009 Mar; 75(5):1395-401. PubMed ID: 19124585
[TBL] [Abstract][Full Text] [Related]
19. Retrospective molecular and phenotypic analysis of poliovirus vaccine strains isolated in Greece.
Pliaka V; Filliponi ME; Kyriakopoulou Z; Ruether IG; Tsakogiannis D; Gartzonika C; Levidiotou-Stefanou S; Markoulatos P
Clin Microbiol Infect; 2011 Oct; 17(10):1554-62. PubMed ID: 21375661
[TBL] [Abstract][Full Text] [Related]
20. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.
Yang CF; Naguib T; Yang SJ; Nasr E; Jorba J; Ahmed N; Campagnoli R; van der Avoort H; Shimizu H; Yoneyama T; Miyamura T; Pallansch M; Kew O
J Virol; 2003 Aug; 77(15):8366-77. PubMed ID: 12857906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
